New Advanced Treatment for Psoriasis Launched in Canada

In our September 2022 blog, we mentioned that a new advanced therapy for psoriasis had been launched in the United States.  It is now in Canada!  The name is very telling as to how the medication works.  “So…TYK2?” Sotyktu© (deucravacitinib) is the newest kid on the block for psoriasis and as the name implies, targets the tyrosine kinase 2 (TYK2) receptor.

TYK2 is the name given to a trigger point (called a receptor) found in many cells involved with the immune system. When the TYK2 receptor is activated, it causes signaling for the inflammatory and immune responses within our bodies. In an autoimmune condition like psoriasis, excess activation of the immune system results in unwanted inflammation in the skin. Sotyktu© blocks the activity of the TYK2 receptor, reducing the production of inflammation to decrease itch, redness, and plaque, providing better management of your psoriasis.

The approval of this treatment is fantastic news for our patients with psoriasis since it provides an oral alternative to injection-based biologic therapies. Moreover, this medication has an excellent safety profile. For those who may feel uneasy about self-injecting, speak to your dermatologist about considering Sotyktu© (deucravacitinib) as a once-daily tablet.

Maher Jibrini is a Student Pharmacist from the University of Waterloo currently doing a rotation at Charlton Health as part of his final year of studies. Maher holds a strong passion for interprofessional collaboration at all levels of healthcare and looks forward to applying his knowledge across various professions in the healthcare & pharmaceutical industry.

Posted in The Charlton Centre | Leave a comment

Charlton Health Launches Biosimilar Video

Charlton Health is pleased to launch a video explaining biosimilars.  We have received many questions about switching from an originator biologic to a biosimilar and this video will help support these questions.

We would love your feedback on this video and the tool we shared on our last blog.  Charlton Health takes great pride in providing educational resources to support patients and we appreciate our readers’ ongoing support of the content we provide.

Carolyn Whiskin is the Pharmacy Manager for Charlton Health. Carolyn specializes in the treatment of autoimmune diseases, pharmaceutical compounding, women’s health, pain, and smoking cessation. Carolyn has won provincial and national awards for her commitment to patient care and public service.

Posted in The Charlton Centre | Leave a comment

Understanding Advanced Therapies in Inflammatory Arthritis – A New Tool

We are very excited to announce that the Canadian Spondylitis Association has added a great tool for patients to their website. This tool was developed by our own clinical pharmacist, Carolyn Whiskin.  The tool was designed to assist patients with rheumatic autoimmune diseases and better understand the risks of being in a state of active disease vs. receiving advanced therapies that can result in low disease activity or remission. It is important to understand that all treatments approved by Health Canada must demonstrate that the health benefits outweigh any risks. Even with that knowledge, patients need confidence that a treatment makes sense for them, and this tool will help in that process. 

Click here to use the Arthritis Treatment Risks tool.

We would love to hear your feedback and hope this is a beneficial resource for you.

Carolyn Whiskin is the Pharmacy Manager for Charlton Health. Carolyn specializes in the treatment of autoimmune diseases, pharmaceutical compounding, women’s health, pain, and smoking cessation. Carolyn has won provincial and national awards for her commitment to patient care and public service.

Posted in The Charlton Centre | Leave a comment

New Autoinjector For Risankizumab (Skyrizi)

Many of the advanced therapies for autoimmune diseases are protein-based medications we refer to as biologics. To avoid stomach digestion, which would render at this medication ineffective, they are given by subcutaneous injection (just under the skin) or infusion. Many of the injections are available as an autoinjector or a prefilled syringe. The syringe requires a person to push the needle through the skin and depress the plunger themselves. Some of these medications require two separate injections for one dose. 

Risankizumab (Skyrizi) is a biologic treatment for moderate to severe plaque psoriasis and psoriatic arthritis. It was initially available as a 75 mg prefilled syringe and each dose required two syringes to be given. Recently, a new formulation was developed whereby the full dose of 150 mg is now contained in one prefilled syringe or an autoinjector. For patients who may not have the dexterity to use the prefilled syringe or simply may not feel comfortable using it, the autoinjector now provides an amazing alternative to enable them to successfully self-inject their medication. For both these conditions, Skyrizi is administered at week 0, week 4, and then every 12 weeks as a maintenance dose. This is a great example of how manufacturers continue to enhance these medications to make them easier for patients to administer.  

Risankizumab has also been recently approved for Crohn’s disease, but in a different format than the dosing used for psoriasis and psoriatic arthritis. When treating Crohn’s Disease, the initial doses are given by infusion in a clinic. Maintenance doses are higher than that used for psoriasis or psoriatic arthritis (600mg) requiring a different type of automated device referred to as an on-body injection. This dispenses the medication through a subcutaneous needle over five minutes while the device has adhered to the skin.

As pharmacists at Charlton Health, it is exciting for us to see this innovation and the ability to grow our resources to support patient care.

Carolyn Whiskin is the Pharmacy Manager for Charlton Health. Carolyn specializes in the treatment of autoimmune diseases, pharmaceutical compounding, women’s health, pain, and smoking cessation. Carolyn has won provincial and national awards for her commitment to patient care and public service.

Posted in The Charlton Centre | Leave a comment

Pharmacy Appreciation Month

March is the month we celebrate the pharmacy profession, and the role pharmacists play in patient care.  As pharmacists at Charlton Health, working with our patients and health professional colleagues across Ontario is a privilege.  We appreciate the trust you place in us as a member of your healthcare team.  We take great pride in the information we provide on a daily basis helping patients navigate and understand their specialty treatments.

Pharmacy teams have been an immense force supporting Canadians through the many challenges we’ve faced. From caring for our communities through the pandemic, helping patients navigate care amidst the current healthcare crisis, managing ongoing drug shortages, and everything in between, the contributions of Canada’s pharmacy professionals have been remarkable!

Over the past few years, pharmacy professionals have grown their roles as immunizers, prescribers, and the first point of contact to the healthcare system for patients across the country. With a healthcare system under strain, pharmacy teams are more essential than ever.

This March, join us in celebrating Pharmacy Appreciation Month!

Carolyn Whiskin is the Pharmacy Manager for Charlton Health. Carolyn specializes in the treatment of autoimmune diseases, pharmaceutical compounding, women’s health, pain, and smoking cessation. Carolyn has won provincial and national awards for her commitment to patient care and public service.

Posted in The Charlton Centre | Leave a comment

Understanding Biosimilars and Non-Medical Switch: The Details

At Charlton Health we specialize in providing biologic medications for many autoimmune conditions. 

Some of these medications have been on the Canadian market for several years and their patent to be the only company who can make the medicine has ended.

This allows other manufacturers to make their own version of the biologic medication. A new supplier of a biologic that has lost its patent, is called a biosimilar

The reason for the name “biosimilar” is because a biologic is produced by programming a living cell to make specific protein-based medication. The specific type of cell used will be different depending on the manufacturer, so their medication must be called “similar” rather than identical. Even batch to batch, the original producer of a biologic can have slight differences. This is why Health Canada requests studies be done with all biosimilars to ensure they are as effective and safe as the original biologic. Studies have also shown that safety and efficacy remain the same when a patient makes this switch.   

Due to the cost savings, many patients around the world have switched from an originator biologic to a biosimilar with great success. In Canada, most provinces have also switched patients to a biosimilar for the purpose of cost savings that would not impact patient outcomes. 

This is referred to as a non-medical switch

Ontario recently announced that the process of switching existing patients to a biosimilar will begin March 31st and this transition period will go until the end of 2023. 

Some of the treatments for autoimmune diseases that are affected by this switch include infliximab (Remicade©), rituximab (Rituxan©), adalimumab (Humira©) and etanercept (Enbrel©).  

At Charlton Health we have dispensed ALL the biosimilars available for each of these treatments over the last several years. They are all very familiar to us and your specialist.

We will work with your specialist to provide any biosimilar needed. 

Our pharmacists will help you be educated on any change!

Charlton works with all support programs; you will have the same financial support you have received from the originator biologic program. 

If you receive an infused medication in one of our clinics, you will continue at the same site with your care team.  If you receive an injectable medication, you will be trained on any device change as each manufacturer has their own patented device. Some of the biosimilar injections offer different features to enhance injection comfort. 

Our pharmacists can review these options with you.  

Based on the worldwide experience and evidence with the biosimilars that exist today, many medical professionals and patient support groups endorse this switch with the understanding that patients are well-informed and educated on any switch.

As always, never hesitate to reach out with any questions or concerns regarding your specialty treatment.  Our team of health professionals and reimbursement specialists are here to support you!

Carolyn Whiskin is the Pharmacy Manager for Charlton Health. Carolyn specializes in the treatment of autoimmune diseases, pharmaceutical compounding, women’s health, pain, and smoking cessation. Carolyn has won provincial and national awards for her commitment to patient care and public service.

Posted in The Charlton Centre | Leave a comment

Traveling with A Biologic Medication

Many of our patients have indicated they are planning a vacation over the winter months to a sunny destination. It is important to note that medication requiring refrigeration is to be kept at 2-8oC during your journey. To ensure the medication is not lost in transport, it must be in your carry-on bag and never under the plane where temperature changes are uncertain.  

Carrying empty Ziploc bags with you is also a good idea. You can get ice from the in-flight attendant to help maintain the temperature in your cooler bag, should your ice packs not be enough for the length of the trip. Soft-sided cooler bags may help maintain fridge temperature for 6-8 hours. However, you may be in transit much longer from the time you leave your home until you arrive at your destination.  In preparation for your trip, you may wish to test your cooler using a small thermometer along with ice packs to mimic the time you will be in transit. This will ensure that when you put the medication in the cooler at the time of travel, you can trust it will remain within the suggested temperature range (2-8oC). 

Biologic medications differ in the amount of time that they can remain at room temperature, ranging from 4 hours to 60 days. If you inadvertently leave your medication out of the fridge, contact us immediately for further direction. Depending on the medication and the amount of time it was left at room temperature, it may not be appropriate to return it to the fridge.

Don’t hesitate to reach out for the pertinent information needed for your specific medication during travel. We are also happy to provide a travel note which may be needed when going through security with a fluid-containing injectable device. Of most importance is to calculate how much medication you will need while away and to order this well in advance of your travel date.

Bon Voyage!

Carolyn Whiskin is the Pharmacy Manager for Charlton Health. Carolyn specializes in the treatment of autoimmune diseases, pharmaceutical compounding, women’s health, pain, and smoking cessation. Carolyn has won provincial and national awards for her commitment to patient care and public service.

Kunal Bhatt, RPh, PharmD, HBSc is a staff pharmacist for Charlton Health. As a 2020 PharmD graduate from the University of Toronto, Kunal possesses a diverse range of experiences from working in hospital and community pharmacy settings. Since January 2021, Kunal was heavily invested in contributing to the efforts against COVID-19 by administering upwards of 5000 COVID-19 vaccines at William Osler Health System’s vaccination clinics. 

Posted in The Charlton Centre | Leave a comment

Publicly Funded Shingles Vaccine Program Expanded

Publicly funded shingles vaccination has been available for many years for adults aged 65-70. Initially, the vaccine provided was Zostavax, which was a live vaccine given as a single dose. Protection decreased with time and by 8 years, very little protection remained. Zostavax is no longer marketed in Canada. In the last few years, the newer non-live shingles vaccine, Shingrix became publicly funded for the 65-70 age group. It is given as 2 doses, two-six months apart. We are still seeing excellent effectiveness 10 years after giving the vaccine. The likelihood of getting shingles increases with age, and 1 in 2 people will get shingles at age 80 and above. Vaccination is recommended for the public from age 50 but is not funded until age 65. For adults who are immunocompromised either by a medical condition or treatment, shingles vaccination is suggested from age 18.

Some private insurance plans pay for vaccinations, however, there are many adults who could benefit from protection who are paying out of pocket. Shingrix does not require a prescription and can be purchased at the pharmacy where a pharmacist can also provide the injection. As a catch-up for those aged 65-70 who did not have access to getting their vaccine due to COVID, the government is extending the publicly funded vaccines to those born in 1949,1950, 1951, and 1952. This means you can still get your complimentary Shingrix if you are turning 71, 72, 73, or 74 up until the end of December 2023. In 2024, the coverage will go back to just 65-70 years of age.

Click here for more information on the shingles vaccine and government coverage.

Carolyn Whiskin is the Pharmacy Manager for Charlton Health. Carolyn specializes in the treatment of autoimmune diseases, pharmaceutical compounding, women’s health, pain, and smoking cessation. Carolyn has won provincial and national awards for her commitment to patient care and public service.

Posted in The Charlton Centre | Leave a comment

What’s in store for 2023…

Happy New Year to our Charlton Family! We enter 2023 with much excitement as treatments for autoimmune diseases continue to expand making our ‘tool chest” bigger. Therapies marketed for psoriasis and psoriatic arthritis are being approved for inflammatory bowel diseases, and new technologies are being implemented to offer slow subcutaneous injections as an alternative to infused medications. Newly discovered mechanisms for treating autoimmune conditions will offer new classes of medication. Advances in COVID prevention and treatment have evolved over the last year with Evusheld and Paxlovid. Pharmacists in Ontario can also prescribe Paxlovid for eligible adults either based on age (people over 60) or high level of infection risk. The RSV (respiratory syncytial virus) vaccine is expected to be approved this year for adults. This comes after the release of the newest pneumonia vaccine, Prevnar 20, in August of 2022. Each year at national and international rheumatic disease, dermatology, and gastroenterology meetings, thousands of posters are presented showing research in these fields. It is inspiring!

As Health Canada approves new therapies, we will share this information with you through our blog series. Stay tuned for the exciting year ahead.

Carolyn Whiskin is the Pharmacy Manager for Charlton Health. Carolyn specializes in the treatment of autoimmune diseases, pharmaceutical compounding, women’s health, pain, and smoking cessation. Carolyn has won provincial and national awards for her commitment to patient care and public service.

Posted in The Charlton Centre | Leave a comment

Our Top Blogs of 2022

As we near the end of 2022, we thought we would share some of our most popular blog posts of the past year with you. We’ve talked about a huge number of subjects this year, but these ones were your favourites!

3. Opening of the Charlton Digestive Disease Centre

2. Health Canada Approves Three New Adalimumab Biosimilars

1. Paxlovid Information

We want to hear from you! Is there a blog topic that you haven’t seen us write about yet? Let us know what you would like to learn about in 2023 by sending us an email!

Posted in The Charlton Centre | Leave a comment